The Company completed sale of asset and rights relating to UltraMist Therapy System on May 7, 2018 to Celularity Inc.
On October 11, 2018, the Company signed merger agreement with Adynxx, Inc. The transaction is expected to close in Q1 2019.
On November 28, 2018, Alliqua announced to spin off its contract-manufacturing subsidiary Aquamed Technologies, and merge the business with TO Pharmaceuticals (OTCPK:TGLP) to establish a clinical-stage pharmaceutical company focused on commercializing cannabinoid-based therapies. The transaction will close in Q1 2019.
The company also intends to pay a special dividend in the range of $1.00 to $1.20 per share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.